ponatinib
otsuka,takeda,incyte
['ponatinib', 'leukemia', 'myeloid']
 outcome of third-line tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase: a propensity score analysis. take home message, ponatinib should be considered after 2nd generation tki failure irrespective of t315im. #ash22 
Assistant Professor @MayoCancerCare @MayoClinic Alumni @MDAndersonNews. Interest in Acute Leukemia and Chronic myeloid disorders. Views are my own